Insmed Incorporated (NASDAQ:INSM – Get Free Report) has been given an average rating of “Buy” by the sixteen brokerages that are presently covering the company, MarketBeat reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $81.53.
A number of research firms have weighed in on INSM. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $72.00 to $74.00 and gave the stock an “overweight” rating in a report on Thursday. Truist Financial lowered their target price on Insmed from $88.00 to $85.00 and set a “buy” rating for the company in a research report on Monday, August 12th. UBS Group upped their price target on Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Mizuho raised their price objective on Insmed from $36.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. Finally, The Goldman Sachs Group upped their target price on Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a report on Wednesday, July 10th.
Get Our Latest Report on Insmed
Insiders Place Their Bets
Institutional Investors Weigh In On Insmed
Hedge funds and other institutional investors have recently made changes to their positions in the business. EntryPoint Capital LLC acquired a new position in Insmed during the 1st quarter valued at about $33,000. Fidelis Capital Partners LLC bought a new stake in Insmed during the first quarter worth $34,000. First Horizon Advisors Inc. raised its position in Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 287 shares during the last quarter. Headlands Technologies LLC bought a new position in Insmed during the 1st quarter valued at $59,000. Finally, CWM LLC boosted its holdings in Insmed by 11.0% during the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 155 shares during the last quarter.
Insmed Stock Down 2.2 %
Shares of NASDAQ:INSM opened at $71.40 on Friday. Insmed has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a market capitalization of $10.61 billion, a PE ratio of -13.65 and a beta of 1.11. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The company has a fifty day moving average of $74.07 and a 200-day moving average of $54.70.
Insmed (NASDAQ:INSM – Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The business had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. During the same period in the previous year, the firm posted ($1.78) earnings per share. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. On average, equities analysts predict that Insmed will post -5.42 EPS for the current fiscal year.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
See Also
- Five stocks we like better than Insmed
- How to Calculate Options Profits
- When Is the Best Time to Invest in Mutual Funds?
- Overbought Stocks Explained: Should You Trade Them?
- Is NVIDIA Stock in a Correction or Consolidation?
- Industrial Products Stocks Investing
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.